Synta Pharmaceuticals Corp. Share Price Nasdaq
Equities
US87162T2069
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Sales 2024 * | 75.76M 6.02B | Sales 2025 * | 361M 28.69B | Capitalization | 4.5B 358B |
---|---|---|---|---|---|
Net income 2024 * | -578M -45.92B | Net income 2025 * | -389M -30.91B | EV / Sales 2024 * | 50.3 x |
Net cash position 2024 * | 694M 55.1B | Net cash position 2025 * | 292M 23.18B | EV / Sales 2025 * | 11.7 x |
P/E ratio 2024 * |
-7.45
x | P/E ratio 2025 * |
-11.6
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.94% |
Latest transcript on Synta Pharmaceuticals Corp.
Managers | Title | Age | Since |
---|---|---|---|
Edward Chiang
FOU | Founder | - | 31/08/11 |
William Sibold
CEO | Chief Executive Officer | - | 07/09/23 |
Rebecca Taub
FOU | Founder | 71 | 30/06/16 |
Members of the board | Title | Age | Since |
---|---|---|---|
Founder | 78 | 31/08/11 | |
Julian Baker
CHM | Chairman | 57 | 14/06/23 |
Ken Bate
BRD | Director/Board Member | 73 | 21/07/16 |
1st Jan change | Capi. | |
---|---|---|
+5.33% | 111B | |
+12.11% | 105B | |
-12.56% | 22.34B | |
-3.70% | 21.93B | |
-6.03% | 18.59B | |
-35.21% | 18.12B | |
-10.86% | 16.96B | |
+5.10% | 13.7B | |
+37.57% | 12.45B |